Prevail Therapeutics’ $75 million Series A financing

Ropes & Gray represented Prevail Therapeutics on the deal

Investors in the round included OrbiMed, Pontifax, RA Capital, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital LLC, Adage Capital Management L.P., and Alexandria Venture Investments. OrbiMed and the Silverstein Foundation for Parkinson’s with GBA incubated and provided seed funding to Prevail.

Prevail is a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. The proceeds of the Series A financing will be used to advance Prevail’s pipeline of adeno-associated virus therapeutics targeting lysosomal dysfunction to treat patients with genetically-defined neurodegenerative diseases.

The Ropes & Gray team was led by life sciences partner Marc Rubenstein (Picture) and included life sciences associate Brad Flint and corporate associate Liam O’Sullivan (all of Boston).

Involved fees earner: Marc Rubenstein – Ropes & Gray; Liam O’Sullivan – Ropes & Gray; Bradford Flint – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: Prevail Therapeutics Inc. ;


Author: Ambrogio Visconti